RedHill Biopharma Ltd. (RDHL)
NASDAQ: RDHL · Real-Time Price · USD
6.40
-0.47 (-6.84%)
At close: Nov 20, 2024, 4:00 PM
6.34
-0.06 (-0.94%)
Pre-market: Nov 21, 2024, 4:56 AM EST
RedHill Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 3.71 | 6.53 | 61.8 | 85.76 | 64.36 | 6.29 | Upgrade
|
| Revenue | 3.71 | 6.53 | 61.8 | 85.76 | 64.36 | 6.29 | Upgrade
|
| Revenue Growth (YoY) | -89.63% | -89.43% | -27.94% | 33.25% | 923.03% | -24.75% | Upgrade
|
| Cost of Revenue | 2.45 | 3.46 | 33.34 | 49.41 | 36.89 | 2.26 | Upgrade
|
| Gross Profit | 1.26 | 3.07 | 28.46 | 36.35 | 27.47 | 4.03 | Upgrade
|
| Selling, General & Admin | 20.97 | 30.98 | 64.03 | 87.99 | 74.66 | 29.81 | Upgrade
|
| Research & Development | 1.86 | 3.53 | 7.28 | 29.5 | 16.49 | 17.42 | Upgrade
|
| Other Operating Expenses | -1.07 | -8.56 | - | - | - | - | Upgrade
|
| Operating Expenses | 21.75 | 25.94 | 71.31 | 117.49 | 91.15 | 47.23 | Upgrade
|
| Operating Income | -20.49 | -22.87 | -42.84 | -81.14 | -63.68 | -43.2 | Upgrade
|
| Interest Expense | - | -0.37 | -41.33 | -16.57 | -12.45 | -0.39 | Upgrade
|
| Interest & Investment Income | 0.33 | 0.09 | 0.14 | 0.05 | 0.18 | 0.44 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.12 | -0.12 | -0.04 | -0.03 | -0.01 | 0.07 | Upgrade
|
| Other Non Operating Income (Expenses) | -8.42 | -7.45 | 12.41 | -0.07 | -0.3 | 0.3 | Upgrade
|
| EBT Excluding Unusual Items | -28.69 | -30.71 | -71.67 | -97.74 | -76.27 | -42.78 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.09 | 0.47 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 35.5 | - | - | - | - | Upgrade
|
| Other Unusual Items | -1.48 | 19.13 | - | - | - | - | Upgrade
|
| Pretax Income | -30.17 | 23.92 | -71.67 | -97.74 | -76.17 | -42.3 | Upgrade
|
| Net Income | -30.17 | 23.92 | -71.67 | -97.74 | -76.17 | -42.3 | Upgrade
|
| Net Income to Common | -30.17 | 23.92 | -71.67 | -97.74 | -76.17 | -42.3 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 697.64% | 320.45% | 32.46% | 27.72% | 22.69% | 28.43% | Upgrade
|
| EPS (Basic) | -38.52 | 92.30 | -1162.89 | -2100.80 | -2091.06 | -1424.76 | Upgrade
|
| EPS (Diluted) | -38.52 | 92.30 | -1162.89 | -2100.80 | -2091.06 | -1424.76 | Upgrade
|
| Free Cash Flow | -24.24 | -35.83 | -29.38 | -65.16 | -48.99 | -40.92 | Upgrade
|
| Free Cash Flow Per Share | -30.94 | -138.28 | -476.76 | -1400.52 | -1344.71 | -1378.05 | Upgrade
|
| Gross Margin | 34.04% | 47.03% | 46.06% | 42.39% | 42.68% | 64.09% | Upgrade
|
| Operating Margin | -552.68% | -350.20% | -69.33% | -94.61% | -98.95% | -686.71% | Upgrade
|
| Profit Margin | -813.97% | 366.25% | -115.97% | -113.98% | -118.36% | -672.45% | Upgrade
|
| Free Cash Flow Margin | -653.76% | -548.71% | -47.55% | -75.98% | -76.11% | -650.41% | Upgrade
|
| EBITDA | -20.94 | -22.15 | -36.56 | -62.99 | -54.94 | -41.99 | Upgrade
|
| EBITDA Margin | - | - | -59.16% | -73.45% | -85.36% | - | Upgrade
|
| D&A For EBITDA | -0.45 | 0.71 | 6.29 | 18.15 | 8.75 | 1.21 | Upgrade
|
| EBIT | -20.49 | -22.87 | -42.84 | -81.14 | -63.68 | -43.2 | Upgrade
|
| EBIT Margin | - | - | -69.33% | -94.61% | -98.95% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.